- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01280487
A Safety Study of Oral ZSTK474 in Patients With Cancer
A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States
- Dana Farber Cancer Institute
-
-
Missouri
-
St Louis, Missouri, United States
- Washington University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
- Fox Chase Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or females ≥18 years of age;
- Histologically-confirmed advanced (metastatic or unresectable) solid tumor - for which available therapy is not effective;
- ECOG performance status score of ≤2 and an expected survival of >8 weeks;
- Recovered from the toxicities of prior chemotherapy, radiotherapy, and other cancer therapies; all toxicities must be determined to be below Grade 2 (assessed using the NCI CTCAE v4.0).
- Adequate blood counts with a hemoglobin (Hgb) of ≥9.0 mg/dL, absolute neutrophil count (ANC) >1,500/mm3, and platelets ≥100,000/mm3 (all without transfusion support);
- Subjects who are willing and able to provide written informed consent.
In the expanded cohort at the MTD only: Subjects must be willing to undergo mandatory biopsies of tumor tissue twice during the first cycle (before and during dosing) and must have tumor tissue in a location accessible to incisional biopsy of a superficial lesion or percutaneous core needle biopsy on an outpatient basis without undue risk to the subject.
Exclusion Criteria:
- Women who are pregnant or breastfeeding;
- Men or women of reproductive potential who are not willing to use acceptable means of contraception while on study drug and for an additional 90 days after the last dose of study drug;
- Body Mass Index (BMI) is ≥30 kg/m2;
- Have primary central nervous system (CNS) tumors or untreated/uncontrolled CNS metastases; Note: Subjects with stable/controlled CNS metastases may be enrolled (i.e., if CNS lesions have been stable in size for at least one month and the subject is off steroid and anti-convulsants).
- Have received any investigational interventional agents within the 4 weeks prior to the start of dosing with ZSTK474;
- Are receiving concurrent anti-tumor chemotherapy, radiotherapy, or immunotherapy - or have received any of these non-investigational agents within the previous 4 weeks or 5-half-lives (whichever is longer) prior to the start of dosing with ZSTK474;
- Are not able or willing to comply with the study procedures, including the study visit schedule;
- Have previously been treated with a phosphatidylinositol 3 kinase (PI3K) inhibitor;
Have serious or significant intercurrent illnesses or underlying diseases, such as:
- Diabetes
- Gastrointestinal disorder
- Hepatic: AST or ALT >2.5 x ULN (or >5.0 x ULN with liver metastases) or serum bilirubin >1.5 x ULN;
- Renal (acute or chronic renal disease or eGFR <55 mL/min)
Cardiovascular:
- Uncontrolled hypertension or blood pressure >140/90 mmHg;
- Symptomatic congestive heart failure;
- Myocardial infarction within the past 6 months;
- Unstable angina pectoris;
- Cardiac arrhythmia;
- Congenital long QT syndrome;
- QTc >450 msec for men or >470 msec for women.
Other:
- Known diagnosis of HIV infection;
- Other ongoing or active infections;
- Psychiatric illness, substance abuse or social situation that would preclude study compliance.
- Other serious concurrent illness that would preclude assessment of drug effect;
- PT/PTT)/APTT/INR >ULN for subjects not on anti-coagulants; INR > 1.5 x ULN for subjects on low dose warfarin.
Current treatment with the following drugs:
- any anti-seizure medications;
- therapeutic anti-coagulant doses of warfarin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oral ZSTK474
Daily oral dosing for 21 days per cycle
|
Daily oral dosing for 21 days each cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose
Time Frame: 21 days
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics
Time Frame: 21 days
|
21 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anthony Olszanski, MD, Fox Chase Cancer Center
- Principal Investigator: Craig Lockhart, MD, Washington University School of Medicine
- Principal Investigator: Geoffrey Shapiro, MD PhD, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ZSTK474-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
European Association for Endoscopic SurgeryWithdrawn
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
Moscow Clinical Scientific CenterRecruitingCecal Neoplasms | Colonic Neoplasms MalignantRussian Federation
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
Clinical Trials on ZSTK474
-
Zenyaku Kogyo Co., Ltd.Completed